China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

BACKGROUND: On May 8, 2018, the China National Medical Products Administration (NMPA) approved anlotinib, an orally administered anti-angiogenesis inhibitor, for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have progressed after treatment with two or more lines of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ming, Chen, Xiaoyuan, Zhang, Hong, Xia, Lin, Tong, Xin, Zou, Limin, Hao, Ruimin, Pan, Jianhong, Zhao, Xiao, Chen, Dongmei, Song, Yuanyuan, Qi, Yueli, Tang, Ling, Liu, Zhifang, Gao, Rong, Shi, Yuankai, Yang, Zhimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585030/
https://www.ncbi.nlm.nih.gov/pubmed/31221221
http://dx.doi.org/10.1186/s40880-019-0383-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585030/
https://www.ncbi.nlm.nih.gov/pubmed/31221221
http://dx.doi.org/10.1186/s40880-019-0383-7

Ejemplares similares